Business Context and Reporting Period
This Form 6-K filing by Sanofi-Synthelabo (Sanofi) is dated June 14, 2004. The report addresses the adjustment of terms for Sanofi's proposed acquisition of Aventis following the approval of Aventis's 2003 dividend at its annual general meeting on June 11, 2004.
Key Financial Metrics and Transaction Terms
The filing does not provide Sanofi's standalone revenue, profit, cash flow, or debt metrics. Instead, it details the adjusted consideration offered to Aventis shareholders:
- Aventis Dividend: Approved at EUR 0.82 per share, with an ex-dividend date of June 15, 2004, and payment on July 15, 2004.
- Standard Entitlement: 5 Sanofi ordinary shares plus EUR 115.08 in cash for every 6 Aventis ordinary shares (equivalent to 0.8333 Sanofi shares and EUR 19.18 cash per Aventis share).
- All Stock Election: 1.1600 Sanofi ordinary shares for each Aventis ordinary share.
- All Cash Election: EUR 68.11 in cash for each Aventis ordinary share.
Material Changes Versus Prior Period
The material change reported is the revision of the acquisition offer terms for Aventis. This adjustment was necessitated by the approval of the Aventis dividend, requiring a reduction in the cash component of the offer to maintain the total value of the transaction as originally structured.
Guidance, Outlook, and Risks
Management Commentary: The filing confirms that the French, U.S., and German offers are being made on substantially the same terms and are intended to expire simultaneously. Completion of the offers remains subject to standard conditions.
Risks and Contingencies: The filing emphasizes that investors must read the Registration Statement on Form F-4 and related prospectuses for important information. It notes that decisions to tender shares under the German Offer must be based exclusively on the German offer document.
Key Facts for Investor Verification
- Verify the final terms of the Sanofi-Aventis merger in the Form F-4 Registration Statement (File No. 333-112314).
- Confirm the ex-dividend date of June 15, 2004, for Aventis shares to ensure eligibility for the EUR 0.82 dividend.
- Review the specific prospectus supplements for the U.S., French, and German offers to understand jurisdiction-specific tender procedures.
- Note that the filing does not contain Sanofi's operational financial results for the period; those are found in the Form 20-F filed on April 2, 2004.